|
|
全程新辅助治疗应用于局部进展期直肠癌的最新进展
|
Abstract:
本综述通过检索全程新辅助治疗(Total neoadjuvant therapy, TNT)模式的最新的临床研究性文章，旨在讨论局部进展期直肠癌(Local advanced rectal cancer, LARC) TNT模式的最新研究进展、临床意义以及对该模式发展的展望。
This review aims to discuss the latest research progress, clinical significance and prospect of TNT for locally advanced rectal cancer (LARC) by searching the latest clinical research articles on TNT for total neoadjuvant therapy.
| [1] | 曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2021, 13(3): 63-69. |
| [2] | Poulsen, L.？., Qvortrup, C., Pfeiffer, P., Yilmaz, M., Falkmer, U. and Sorbye, H. (2015) Review on Adju-vant Chemotherapy for Rectal Cancer—Why Do Treatment Guidelines Differ so Much? Acta Oncologica, 54, 437-446.
https://doi.org/10.3109/0284186X.2014.993768 |
| [3] | 欧阳淦露. 全程新辅助治疗在高危局部晚期直肠癌患者中的疗效和安全性分析[J]. 中华胃肠外科杂志, 2019, 22(4): 349-359. https://doi.org/10.3760/cma.j.issn.1671-0274.2019.04.007 |
| [4] | Fernández-Martos, C., Pericay, C., Aparicio, J., et al. (2010) Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecit-abine Plus Oxaliplatin (CAPOX) Compared with Induction CAPOX Followed by Concomitant Chemoradio-Therapy and Surgery in Magnetic Resonance Imaging Defined, Locally Advanced Rectal Cancer: Grupo Cancer de Recto 3 Study. Journal of Clinical Oncology, 28, 859-865.
https://doi.org/10.1200/JCO.2009.25.8541 |
| [5] | Fernández-Martos, C., Garcia-Albeniz, X., Pericay, C., et al. (2015) Chemoradiation, Surgery and Adjuvant Chemotherapy Versus Induction Chemotherapy Followed by Chemoradi-ation and Surgery: Long-Term, Results of the Spanish GCR-3 Phase II Randomized Trial. Annals of Oncology, 26, 1722-1728. https://doi.org/10.1093/annonc/mdv223 |
| [6] | Reibetanz, J. and Germer, C.T. (2015) Intensivierte adju-vante Chemotherapie mit FOLFOX beim multimodal behandelten Rektumkarzinom [Intensified Adjuvant Chemotherapy with FOLFOX in the Multimodal Treatment of Rectal Cancer]. Der Chirurg, 86, 79. https://doi.org/10.1007/s00104-014-2977-6 |
| [7] | Ludmir, E.B., Palta, M., Willett, C.G., et al. (2017) Total Neoad-juvant Therapy for Rectal Cancer: An Emerging Option. Cancer, 123, 1497-1506. https://doi.org/10.1002/cncr.30600 |
| [8] | NCCN (2022) National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 1, NCCN. |
| [9] | 龙飞, 胡桂, 马敏, 等. 2021.V1版NCCN临床实践指南: 结肠癌/直肠癌更新解读(外科部分) [J]. 临床外科杂志, 2021, 29(5): 401-404. |
| [10] | 梁小波. 2016版中国局部进展期直肠癌诊疗专家共识解读[J]. 临床外科, 2017, 25(4): 248-250. |
| [11] | Kim, H.S. and Kim, N.K. (2020) Challenges and Shifting Treatment Strategies in the Surgical Treatment of Locally Advanced Rectal Cancer. Annals of Gastroenterological Surgery, 4, 379-385. https://doi.org/10.1002/ags3.12349 |
| [12] | Erlandsson, J., Holm, T., Pet-tersson, D., Berglund, ？., Cedermark, B., Radu, C., Johansson, H., Machado, M., Hjern, F., Hallb？？k, O., Syk, I., Glimelius, B. and Martling, A. (2017) Optimal Fractionation of Preoperative Radiotherapy and Timing to Surgery for Rectal Cancer (Stockholm III): A Multicentre, Randomised, Non-Blinded, Phase 3, Non-Inferiority trial. The Lancet Oncology, 18, 336-346. https://doi.org/10.1016/S1470-2045(17)30086-4 |
| [13] | Kim, J.S., Jeong, S.Y., Shin, R., Oh, H.K., Park, K.J. and Park, J.G. (2012) Preoperative versus Postoperative Chemoradiotherapy for Locally Advanced Rec-tal Cancer. European Journal of Surgical Oncology, 38, 831.
https://doi.org/10.1016/j.ejso.2012.06.307 |
| [14] | Sauer, R., Liersch, T., Merkel, S., et al. (2012) Preoperative ver-sus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial after a Median Follow-Up of 11 Years. Journal of Clinical Oncology, 30, 1926-1933. https://doi.org/10.1200/JCO.2011.40.1836 |
| [15] | van Gijn, W., Marijnen, C.A., Nagtegaal, I.D., et al. (2011) Pre-operative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer: 12-Year Follow-Up of the Multicentre, Randomised Controlled TME Trial. The Lancet Oncology, 12, 575-582. https://doi.org/10.1016/S1470-2045(11)70097-3 |
| [16] | Ogura, A., Konishi, T., Cunningham, C., et al. (2019) Neo-adjuvant (Chemo) Radiotherapy with Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recur-rence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients with Low cT3/4 Rectal Cancer. Journal of Clinical Oncology, 37, 33-43.
https://doi.org/10.1200/JCO.18.00032 |
| [17] | Breugom, A.J., Swets, M., Bosset, J.F., et al. (2015) Adjuvant Chem-otherapy after Preoperative (chemo) Radiotherapy and Surgery for Patients with Rectal Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. The Lancet Oncology, 16, 200-207. https://doi.org/10.1016/S1470-2045(14)71199-4 |
| [18] | Hong, T.S. and Ryan, D.P. (2018) Total Neoadjuvant Ther-apy for Locally Advanced Rectal Cancer-The New Standard of Care? JAMA Oncology, 4, e180070. https://doi.org/10.1001/jamaoncol.2018.0070 |
| [19] | Dossa, F., Chesney, T.R., Acuna, S.A. and Baxter, N.N. (2017) A Watch-and-Wait Approach for Locally Advanced Rectal Cancer after a Clinical Complete Response Following Neoad-juvant Chemoradiation: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 2, 501-513.
https://doi.org/10.1016/S2468-1253(17)30074-2 |
| [20] | Bahadoer, R.R., Dijkstra, E.A., van Etten, B., et al. (2021) Short-Course Radiotherapy Followed by Chemotherapy before Total Mesorectal Excision (TME) versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial. [Published Correction Appears in Lancet Oncology, 2021 Feb, 22(2): e42]. The Lancet Oncology, 22, 29-42. |
| [21] | Schrag, D., Weiser, M., Saltz, L., et al. (2019) Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance). Clinical Tri-als, 16, 165-175.
https://doi.org/10.1177/1740774518824539 |
| [22] | Abdalla, A., Aref, A., Alame, A., et al. (2020) Does Response to Upfront FOLFOX Predict Eventual Clinical and Pathological Response after Completion of Total Neoadjuvanttherapy for Patients Diagnosed with Rectal Cancer? Observations from a Phase II Clinical Trial. Diseases of the Colon & Rectum, 63. |
| [23] | Cercek, A., Roxburgh, C.S.D., Strombom, P., et al. (2018) Adoption of Total Neoadjuvant Therapy for Local-ly Advanced Rectal Cancer. JAMA Oncology, 4, e180071. https://doi.org/10.1001/jamaoncol.2018.0071 |
| [24] | Rouanet, P., Rullier, E., Lelong, B., et al. (2017) Tailored Treat-ment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Pre-liminary Results of the French Phase II Multicenter GRECCAR4 trial. Diseases of the Colon & Rectum, 60, 653-663.
https://doi.org/10.1097/DCR.0000000000000849 |
| [25] | Forastiere, A.A., Zhang, Q., Weber, R.S., Maor, M.H., Goepfert, H., Morrison, T.F.P., Glisson, B., Trotti, A., Ridge, J.A., Thorstad, W., Wagner, H., Ensley, J.F. and Cooper, J.S. (2013) Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients with Locally Advanced Larynx Cancer. Journal of Clinical Oncology, 31, 845-852. https://doi.org/10.1200/JCO.2012.43.6097 |
| [26] | Benson, A.B., Venook, A.P., Al-Hawary, M.M., et al. (2018) Rectal Cancer, Version 2. 2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehen-sive Cancer Network, 16, 874-901.
https://doi.org/10.6004/jnccn.2018.0061 |
| [27] | Fokas, E., Allg？uer, M., Polat, B., et al. (2019) Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapyfor Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. Journal of Clinical Oncology, 37, 3212-3222. https://doi.org/10.1200/JCO.19.00308 |
| [28] | Fokas, E., Schlenska-Lange, A., Polat, B., Klautke, G., Grabenbauer, G.G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.L., Kirste, S., Jacobasch, L., Allg？uer, M., Flentje, M., Germer, C.T., Grützmann, R., Hildebrandt, G., Schwarzbach, M., Bechstein, W.O., Sülberg, H., Friede, T., Gaedcke, J., Ghadimi, M., Hofheinz, R.D., R？del, C. and German Rectal Cancer Study Group (2022) Chemoradiotherapy Plus Induc-tion or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer: Long-Term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncology, 8, e215445. https://doi.org/10.1001/jamaoncol.2021.5445 |
| [29] | Garcia-Aguilar, J., Patil, S., Gollub, M.J., et al. (2022) Organ Preservation in Patients with Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy. Journal of Clinical On-cology, 40, 2546-2556. |
| [30] | George, T.J., Yothers, G., Hong, T.S., Russell, M.M., You, Y.N., Parker, W., Jacobs, S.A., Lucas, P.C., Gollub, M.J., Hall, W.A., Kachnic, L.A., Vijayvergia, N. and Wolmark, N. (2019) NRG-GI002: A Phase II Clinical Trial Platform Using Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (LARC)—First Experimental Arm (EA) Initial Results. Journal of Clinical Oncology, 37, Article 3505. https://doi.org/10.1200/JCO.2019.37.15_suppl.3505 |
| [31] | Aref, A. and Abdalla, A. (2022) Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Induction or Consolidation Chemotherapy? Journal of Clinical Oncology, 40, 2515-2519. https://doi.org/10.1200/JCO.22.00506 |
| [32] | Rahma, O.E., Yothers, G., Hong, T.S., et al. (2021) Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results from the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA Oncology, 7, 1225-1230. https://doi.org/10.1001/jamaoncol.2021.1683 |
| [33] | Cise？, B., Pietrzak, L., Michalski, W., et al., for the Polish Colo-rectal Study Group. (2019) Long-Course Preoperative Chemoradiation versus 5 × 5 Gy and Consolidation Chemotherapy for Clinical T4 and Fixed Clinical T3 Rectal Cancer: Long-Term Results of the Randomized Polish II Study. Annals of Oncology, 30, 1298-1303.
https://doi.org/10.1093/annonc/mdz186 |
| [34] | Chatila, W.K., Kim, J.K., Walch, H., Marco, M.R., Chen, C.T., Wu, F., Omer, D.M., Khalil, D.N., Ganesh, K., Qu, X., Luthra, A., Choi, S.H., Ho, Y.J., Kundra, R., Groves, K.I., Chow, O.S., Cercek, A., Weiser, M.R., Widmar, M., Wei, I.H., Pappou, E.P., Nash, G.M., Paty, P.B., Shi, Q., Vakiani, E., Duygu, S.S., Donoghue, M.T.A., Solit, D.B., Berger, M.F., Shia, J., Pelossof, R., Romesser, P.B., Yaeger, R., Smith, J.J., Schultz, N., Sanchez-Vega, F. and Garcia-Aguilar, J. (2022) Genomic and transCriptomic Determinants of Response to Neoadjuvant Therapy in Rectal Cancer. Nature Medicine, 28, 1646-1655. https://doi.org/10.1038/s41591-022-01930-z |
| [35] | van der Valk, M.J.M., Hilling, D.E., Bastiaannet, E., et al. (2018) Long-Termoutcomes of Clinical Complete Responders after Neoadjuvanttreatment for Rectal Cancer in the Inter-national Watch & WaitDatabase (IWWD): An International Multicentre Registry Study. The Lancet, 391, 2537-2545. https://doi.org/10.1016/S0140-6736(18)31078-X |
| [36] | Smith, J.J., Strombom, P., Chow, O.S., et al. (2019) As-sessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients with a Completeresponse after Neoadjuvant Thera-py. JAMA Oncology, 5, e185896.
https://doi.org/10.1001/jamaoncol.2018.5896 |
